Literature DB >> 21364078

Differentiation syndrome in patients with acute promyelocytic leukemia.

Jane E Rogers1, Daisy Yang.   

Abstract

OBJECTIVE: To review the pathophysiology, risk factors, and management of differentiation syndrome (DS) associated with acute promyelocytic leukemia (APL). DATA SOURCE: A MEDLINE search was conducted (1977-November 2010) using the terms APL, DS, all-trans retinoic acid (ATRA), retinoic acid syndrome, and arsenic trioxide (ATO). METHODS OF STUDY SELECTION: English articles identified from the MEDLINE search were evaluated. DATA EXTRACTION AND SYNTHESIS: With ATRA, ATO, and chemotherapy, a complete remission is achievable for most newly diagnosed APL patients. However, treatment with the differentiating agents, ATRA and ATO, can lead to the development of DS. Signs and symptoms of this syndrome include hyperleukocytosis and cardiorespiratory compromise. Severe complications can develop, if DS is not recognized early and treated promptly with corticosteroids. In addition, patients with a high white blood cell count at diagnosis may benefit from prophylactic steroids.
CONCLUSIONS: Early recognition and prompt initiation of corticosteroids are key factors in the management of DS. Healthcare professionals need to be familiar with this complication which can arise from differentiation agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21364078     DOI: 10.1177/1078155211399163

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  14 in total

1.  Myopericarditis in a pregnant woman with acute promyelocytic leukemia.

Authors:  Andrew Oehler; Shimoli Shah
Journal:  J Cardiol Cases       Date:  2014-08-19

2.  Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.

Authors:  Haiyan He; Ran An; Jian Hou; Weijun Fu
Journal:  Front Med       Date:  2017-04-19       Impact factor: 4.592

Review 3.  Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome.

Authors:  Luciano Cardinale; Francesco Asteggiano; Federica Moretti; Federico Torre; Stefano Ulisciani; Carmen Fava; Giovanna Rege-Cambrin
Journal:  World J Radiol       Date:  2014-08-28

4.  Adjuvant potential of low dose all-trans retinoic acid during oral typhoid vaccination in Zambian men.

Authors:  M M Lisulo; M C Kapulu; R Banda; E Sinkala; V Kayamba; S Sianongo; P Kelly
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

5.  Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-α and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells.

Authors:  Li-min Xu; Yue-juan Zheng; Ying Wang; Yang Yang; Fan-fan Cao; Bin Peng; Xiong-fei Xu; Hua-zhang An; Ao-xiang Zheng; Deng-hai Zhang; Georges Uzan; Yi-zhi Yu
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

6.  HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.

Authors:  Lanlan Tang; Wenwen Chai; Fanghua Ye; Yan Yu; Lizhi Cao; Minghua Yang; Min Xie; Liangchun Yang
Journal:  Oncotarget       Date:  2017-04-18

7.  Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits.

Authors:  Lucas Miyake Okumura; Patrícia Carvalho Baruel Okumura; Cleni Veroneze
Journal:  Rev Bras Hematol Hemoter       Date:  2016-12-23

8.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy.

Authors:  Jing Jin; Adrian Britschgi; Anna M Schläfli; Magali Humbert; Deborah Shan-Krauer; Jasmin Batliner; Elena A Federzoni; Marion Ernst; Bruce E Torbett; Shida Yousefi; Hans-Uwe Simon; Mario P Tschan
Journal:  Oxid Med Cell Longev       Date:  2018-03-18       Impact factor: 6.543

10.  Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California.

Authors:  Renata Abrahão; Raul C Ribeiro; Bruno C Medeiros; Ruth H Keogh; Theresa H M Keegan
Journal:  Cancer       Date:  2015-08-11       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.